Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you're looking at weight loss injections in the Benfleet area, the two medicines with the strongest clinical track record in the UK are tirzepatide (Mounjaro) and semaglutide (Wegovy). Both are prescription-only, meaning a qualified prescriber must assess your suitability before treatment can begin — no online pharmacy can lawfully supply them without that step. What the trial evidence shows is striking: in the SURMOUNT-1 study, tirzepatide produced an average body-weight reduction of around 20% over 72 weeks, while STEP 1 recorded approximately 15% with semaglutide 2.4mg — figures that set these medicines apart from older approaches. UK-licensed weight loss injections are available through regulated private pharmacies, so geography matters less than you might expect: a same-day clinical review and next-working-day delivery means access doesn't depend on what's available locally in Benfleet.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The SURMOUNT-1 and STEP 1 trials are the backbone of UK clinical guidance on these medicines. SURMOUNT-1 randomised 2,539 adults with obesity over 72 weeks; those on the highest tirzepatide dose lost an average of roughly 20–21% of their body weight alongside a reduced-calorie diet and increased activity. STEP 1, covering 68 weeks of semaglutide 2.4mg, recorded around 15% average reduction. Both are cited directly in NICE's technology appraisal of tirzepatide (TA1026), which recommended tirzepatide for NHS use in December 2024, a step that requires NICE to be satisfied that a medicine's benefits are both meaningful and well-evidenced.
The reason those percentages matter isn't academic. A 15–20% reduction in body weight for someone who weighs 100kg is 15–20kg, enough to produce measurable improvements in blood pressure, cholesterol, sleep apnoea and joint load. That's the clinical context behind what is sometimes casually called a "weight loss jab".
A question our prescribers hear most weeks is whether the medicine does the work on its own. It doesn't. Both medicines are licensed alongside a reduced-calorie diet and increased physical activity; the trial participants followed structured lifestyle programmes. The injection changes your appetite signals significantly (most people find portions fall naturally) but building sustainable habits alongside it makes the difference between results that last and weight that returns when treatment stops.
Private eligibility follows the medicines' SmPCs: adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, prediabetes or obstructive sleep apnoea. BMI thresholds are 2.5 kg/m² lower for some ethnic backgrounds under UK clinical guidance. BMI alone doesn't settle the question, the prescriber weighs up the whole picture, including your medical history, current medicines and any contraindications.
For context on what the NHS route looks like, you can read through how GP-prescribed weight loss injections work. The NHS currently phases access by how many qualifying conditions a person has, the threshold for Cohort 2, active from June 2026, is a BMI of 35–39.9 plus four or more of five specified conditions. Many people in Benfleet and the wider Essex area will not meet those criteria yet, or will face significant waiting times through specialist services.
Private treatment through a GPhC-registered online pharmacy sidesteps the waiting list, provided clinical criteria are met. Every consultation at nume is reviewed personally by a GPhC-registered Independent Prescriber (not processed by software) on the day it's submitted. Identity and weight are verified before any prescription is issued.
The side-effect profile of both medicines is dominated by gastrointestinal symptoms: nausea, loose stools, constipation, indigestion and belching are the most commonly reported. These tend to peak in the first days after starting or stepping up a dose, then ease as the body adjusts, though not always, and some people do find a particular dose doesn't suit them and need to discuss it with their prescriber.
Less common but serious effects are worth knowing. In January 2026, the MHRA issued a Drug Safety Update for GLP-1 medicines flagging acute pancreatitis as an infrequent but potentially serious risk; severe, persistent abdominal pain that spreads to the back, with or without vomiting, warrants urgent medical attention rather than waiting it out. The NHS tirzepatide medicines page sets out the full side-effect list with practical guidance on which symptoms need a call to 111 or 999.
Anyone taking oral contraceptives while on tirzepatide should add a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, absorption of the pill may be reduced. This doesn't apply in the same way to semaglutide, but it's worth raising at your consultation either way. These medicines aren't recommended in pregnancy, while breastfeeding, or for anyone trying to conceive; under-18s are outside the licensed indication.
Good injection technique matters for tolerability. Rotating sites between the abdomen, thigh and upper arm, and using a fresh needle each time, reduces the chance of injection-site reactions. If you're curious about how weight loss injections can affect the face, including changes in facial volume that some people notice, that's covered in detail separately. A pack of alcohol swabs is worth having at home for cleaning the site before injecting.
Because these are prescription-only medicines, the only lawful route is clinical assessment followed by a valid prescription from a registered prescriber. That assessment can happen entirely online through a GPhC-registered pharmacy, you don't need to travel to a clinic in Benfleet or elsewhere. The practical benefits of regulated weight loss injections include the fact that a legitimate service verifies your identity, checks your weight, reviews your medical history and notifies your GP, all before a prescription is written.
Anyone comparing providers on price alone is asking the wrong question for a prescription medicine. What matters is whether the pharmacy is on the GPhC register, whether a real prescriber reviews every consultation, and whether the medicine comes through the licensed UK supply chain. The MHRA has warned repeatedly about counterfeit pens sold online; fake products have contained incorrect substances, including insulin, and have led to hospitalisations. If you want to understand how tirzepatide, semaglutide and liraglutide compare as options, our guide to the three main weight loss injections available in the UK sets out the differences clearly. For a fuller look at how private costs are structured (and what transparent pricing actually covers) the guide to weight loss injection costs covers the market honestly.
Our weight loss treatment overview explains the full range of options available through nume, and our clinical team background is published for anyone who wants to check the credentials behind the service. If you're ready to find out whether treatment is suitable for you, start your free consultation at the treatment page, it's reviewed by a prescriber the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.